INCLINE VILLAGE, Nev.,
Feb. 17, 2017 /PRNewswire/ -- PDL
BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that
John P. McLaughlin, PDL's president
and chief executive officer, will participate in a fireside chat at
the 2017 RBC Capital Markets Global Healthcare Conference next week
in New York. The session will be
webcast live and will occur on Wednesday
February 22, 2017 at 2:35 p.m.
EST.
To access the live and subsequently archived webcast of the
presentation, go to the company's website at
http://www.pdl.com and go to "Presentations and Events."
Please connect to the website at least 15 minutes prior to the
presentation to allow for any software download that may be
necessary. The archived webcast will be available for at least
seven days following the presentation.
About PDL BioPharma
PDL seeks to provide a significant
return for its shareholders by acquiring and managing a portfolio
of companies, products, royalty agreements and debt facilities in
the biotech, pharmaceutical and medical device industries. In
late 2012, PDL began providing alternative sources of capital
through royalty monetizations and debt facilities and in 2016,
began making equity investments in commercial stage companies, the
first being Noden Pharma DAC. PDL has committed over
$1.4 billion and funded approximately
$1.1 billion in these investments to
date.
PDL was formerly known as Protein Design Labs, Inc. and changed
its name to PDL BioPharma, Inc. in 2006. PDL was founded in
1986 and is headquartered in Incline
Village, Nevada. PDL pioneered the humanization of
monoclonal antibodies and, by doing so, enabled the discovery of a
new generation of targeted treatments for cancer and immunologic
diseases for which it has received significant royalty revenue.
NOTE: PDL BioPharma and the PDL BioPharma logo are
considered trademarks of PDL BioPharma, Inc.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/pdl-biopharma-to-present-at-the-2017-rbc-capital-markets-global-healthcare-conference-300409359.html
SOURCE PDL BioPharma, Inc.